These findings demonstrate that LARS deficiency impairs glycolytic metabolism and attenuates the malignant behavior of DLBCL cells, providing compelling evidence that LARS drives tumor progression through metabolic reprogramming. The gene discussed is LARS1; the disease is neoplasm.